Valugen Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.60 Cr
- Paid Up Capital ₹ 1.60 Cr
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 497.87%
- Profit Growth 611.67%
- Ebitda 592.28%
- Net Worth 130.00%
- Total Assets 138.08%
About Valugen Pharma
Valugen Pharma Private Limited (VPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 09 September 2010 and has a history of 14 years and five months. Its registered office is in Bangalore, Karnataka.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.60 Cr and a paid-up capital of Rs 1.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sriram Iyer, Jayashree Iyer, and Girish Joshi serve as directors at the Company.
Company Details
- Location Bangalore, Karnataka
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232KA2010PTC055115
-
Company No.
055115
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Sep 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Valugen Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sriram Iyer
|
Managing Director | 09-Sep-2010 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Girish Joshi
|
Whole-Time Director | 16-Mar-2015 | Current |
|
Jayashree Iyer
|
Whole-Time Director | 09-Sep-2010 | Current |
Financial Performance of Valugen Pharma.
Valugen Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 497.87% increase. The company also saw a substantial improvement in profitability, with a 611.67% increase in profit. The company's net worth Soared by an impressive increase of 130%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Valugen Pharma?
In 2023, Valugen Pharma had a promoter holding of 51.00% and a public holding of 49.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Valugen Pharma?
Unlock and access historical data on people associated with Valugen Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Valugen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Valugen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
